A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here
Monday, 11 July 2011
The Financial Times article goes on to discuss its assessment of the market value of Lipitor, which currently accounts for one-fifth of Pfizer's sales.
Source: "Pfizer gets $800m boost for Lipitor", Andrew Jack, 10 July 2011